Clinical Research Directory

Inclusion Criteria: 1. Children and adolescents between 7 and 21 years of age. 2. A history at least one infection due to ESC-R Enterobacteriaceae. ESC-R isolates will be defined as those non-susceptible to ceftriaxone, cefotaxime, or ceftazidime. 3. Parent/guardian and participant must be able to attend baseline and follow-up study visits. 4. Subject must be willing and able to provide written informed consent or assent (as appropriate by age). Exclusion Criteria: 1. Patients with any history of malignancy or any immunocompromised state (e.g. absolute neutrophil count outside the normal range) induced by disease or therapy will be excluded. 2. Patients with past or current use of systemic immunosuppressive agents will be excluded. Receipt of non-systemic agents such as inhaled, nasal, or topical steroids or immune-modulating agents are allowed. 3. Lack of intestinal carriage of ESC-R Enterobacteriaceae (negative selective stool culture for ESC-R Enterobacteriaceae). 4. Allergy or hypersensitivity to omeprazole and polyethylene glycol. 5. Pregnancy. 6. Current history of frequent (\>1 per week) vomiting. 7. Active inflammatory gastrointestinal disease, such as inflammatory bowel disease 8. Active mucositis or acute graft versus host disease of the gastrointestinal tract 9. Concurrent abdominal radiation therapy. 10. Inability to tolerate nasogastric tube placement or contraindication to having an NG tube placed. 11. Presence of a ventriculoperitoneal shunt or other intrabdominal device, receipt of renal dialysis, presence of ascites, or other conditions/devices that would increase the risk of peritonitis. 12. Bleeding diatheses 13. Patients with current active ESC-R Enterobacteriaceae infection who have not yet completed antibiotic treatment will be excluded until their treatment is completed \-